AETHLON MEDICAL INC (AEMD) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-Q, AETHLON MEDICAL INC's filing signal continuing negative.

Aethlon Medical, Inc. is a clinical-stage medical therapeutic company focused on developing the Hemopurifier(R), an immunotherapeutic device designed for applications in cancer and life-threatening viral infections. The Hemopurifier utilizes a proprietary lectin-based mechanism to remove harmful extracellular vesicles and enveloped viruses from biological fluids. The company is currently conducting Phase 1 safety, feasibility, and dose-finding clinical trials for the Hemopurifier in Australia for patients with solid tumors, with plans to initiate similar trials in India. The U.S. Food and Drug Administration (FDA) has designated the Hemopurifier as a "Breakthrough Device" for two independent indications. Aethlon is also exploring additional clinical uses for the Hemopurifier, including in areas like Long COVID and organ transplantation.

The company did not generate revenue in the fiscal years ended March 31, 2025, and March 31, 2024. Future revenue is expected to be driven by the commercialization of the Hemopurifier.